Pre-Clinical Assessment of (177)Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease

Studies from this laboratory have demonstrated the potential of targeting HER2 for therapeutic and imaging applications with medically relevant radionuclides. To expand the repertoire of trastuzumab as a radioimmunoconjugate (RIC) vector, use of (177)Lu was investigated. The combination of a 6.7 d h...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Geoffrey L., Baidoo, Kwamena E., Keller, Lanea M. M., Albert, Paul S., Brechbiel, Martin W., Milenic, Diane E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250925/
https://www.ncbi.nlm.nih.gov/pubmed/22229017
http://dx.doi.org/10.3390/ph5010001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250925/
https://www.ncbi.nlm.nih.gov/pubmed/22229017
http://dx.doi.org/10.3390/ph5010001

Ejemplares similares